Life
FDA approves Gazyva for primary membranous nephropathy. Who is it for?
The first drug approved specifically for primary membranous nephropathy is for adults at risk of worsening disease. A two-year trial measured how often excess protein in the urine went into remission.
November 16, 2026 · 3 min read
